<DOC>
	<DOCNO>NCT00300911</DOCNO>
	<brief_summary>The present study aim evaluate effect rosiglitazone treatment cardiac function compare metformin</brief_summary>
	<brief_title>Effects Rosiglitazone Plasma BNP Levels Left Ventricular Dysfunction</brief_title>
	<detailed_description>Large scale clinical trial report fluid retention increase plasma volume ( 6 % 7 % ) glitazone therapy , increase incidence peripheral edema occur 2 % 5 % patient . Some evidence suggest effect may relate increase endothelial cell permeability induce glitazones therapy . Others report glitazones may interfere renal hemodynamics . In controlled clinical trial , frequency new onset congestive heart failure low glitazones treat patient . The incidence congestive heart failure high patient receive combination therapy insulin glitazones . Only study compare rosiglitazone metformin cardiac safety . Recently study report reversible increase endothelial cell permeability albumin culture pulmonary arterial cell treat rosiglitazone . To knowledge , clinical study publish show reversibility cardiac adverse effect rosiglitazone treatment continue .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Type 2 diabetes mellitus treat oral hypoglycemic agent diet Without symptom find heart failure Normal liver enzymes renal function Any know coronary artery disease , congestive hearth failure , renal disease liver disease Any treatment heart failure diuretic reason .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>Natriuretic Peptide , Brain</keyword>
	<keyword>Heart Failure , Congestive</keyword>
</DOC>